Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$6.31
-2.0%
$7.24
$1.78
$10.40
N/A1.36137,927 shs7,151 shs
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
$0.00
$0.00
$0.00
$0.07
N/A2.9819 shsN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
$8.00
$0.80
$4.80
$122.94M1.07177,606 shsN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$10.98
+1.2%
$10.50
$0.29
$3.72
$466.31M3.931.22 million shs3.40 million shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$2.38
-2.1%
$2.29
$1.90
$4.01
$69.40M0.61187,370 shs195,617 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00%-7.12%-20.93%+16.85%+204.83%
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
0.00%0.00%0.00%0.00%-85.71%
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
+1.20%+44.85%+51.24%+157.75%+25.63%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.00%+17.53%+2.59%+12.26%-31.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.892 of 5 stars
0.05.00.00.03.30.00.0
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.9301 of 5 stars
0.01.00.00.03.31.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00
N/AN/AN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
0.00
N/AN/AN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
0.00
N/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00
N/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest UMRX, SBPH, PULM, RGRX, and VTGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$7.81MN/AN/AN/A$2.45 per shareN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
$80KN/AN/AN/AN/AN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
N/AN/AN/AN/A$2.16 per shareN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$22.50M20.72N/AN/A$1.04 per share10.56
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$490K141.63N/AN/A$2.44 per share0.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$6.94M-$3.34N/AN/A-122.46%-94.97%-84.57%8/12/2025 (Estimated)
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
-$1.73MN/A0.00N/AN/AN/AN/AN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)

Latest UMRX, SBPH, PULM, RGRX, and VTGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million
5/15/2025Q1 2025
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A-$0.50N/A-$0.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/AN/AN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
8.90
8.90
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
N/A
5.11
5.11
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.18
2.90
2.90
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
6.51
6.51
CompanyEmployeesShares OutstandingFree FloatOptionable
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
20N/AN/ANot Optionable
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
3N/AN/ANot Optionable
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
3017.27 millionN/ANot Optionable
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
7242.47 millionN/ANot Optionable
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4029.16 million28.78 millionOptionable

Recent News About These Companies

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha
Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Pulmatrix stock logo

Pulmatrix NASDAQ:PULM

$6.36 -0.08 (-1.32%)
As of 07/11/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

RegeneRx Biopharmaceuticals stock logo

RegeneRx Biopharmaceuticals OTCMKTS:RGRX

$0.0002 0.00 (0.00%)
As of 07/11/2025

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Spring Bank Pharmaceuticals stock logo

Spring Bank Pharmaceuticals NASDAQ:SBPH

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$2.38 -0.05 (-2.06%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$2.39 +0.01 (+0.42%)
As of 07/11/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.